Novo Nordisk and Eli Lilly's weight-loss drugs offer substantial net health benefits and are also cost-effective at current prices – but will still pose an affordability challenge to US healthcare.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback